MX2021009383A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents

Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Info

Publication number
MX2021009383A
MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A
Authority
MX
Mexico
Prior art keywords
methods
lysosomal storage
storage diseases
disorders associated
treating symptoms
Prior art date
Application number
MX2021009383A
Other languages
English (en)
Inventor
Nigel Patrick Somerville Crawford
Tanya Zaremba Fischer
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2021009383A publication Critical patent/MX2021009383A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a métodos para tratar o prevenir particulares síntomas y trastornos que se asocian con enfermedades del almacenamiento lisosómico utilizando compuestos de quinuclidina de la fórmula (I), opcionalmente combinados con terapia de reemplazo enzimático. Esto incluye parálisis de la mirada supranuclear, incluyendo parálisis de la mirada sacádica horizontal y vertical, y deficiencias cognitivas o trastornos de la marcha, tales como en un paciente que tenga enfermedad de Gaucher o enfermedad de Niemann-Pick tipo C. También se describe una composición farmacéutica que comprende un compuesto de quinuclidina para su uso en dichos métodos.
MX2021009383A 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. MX2021009383A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US202062962647P 2020-01-17 2020-01-17
PCT/US2020/016441 WO2020163245A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Publications (1)

Publication Number Publication Date
MX2021009383A true MX2021009383A (es) 2021-09-10

Family

ID=69743942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009383A MX2021009383A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2021009384A MX2021009384A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009384A MX2021009384A (es) 2019-02-04 2020-02-03 Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.

Country Status (13)

Country Link
US (2) US20220023273A1 (es)
EP (2) EP3920913A1 (es)
JP (2) JP2022519274A (es)
KR (2) KR20210123352A (es)
CN (2) CN113645969A (es)
AU (2) AU2020217659A1 (es)
BR (2) BR112021015099A2 (es)
CA (2) CA3128039A1 (es)
IL (2) IL285187A (es)
MX (2) MX2021009383A (es)
SG (2) SG11202107842QA (es)
TW (2) TW202045168A (es)
WO (2) WO2020163244A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
WO2012129084A2 (en) * 2011-03-18 2012-09-27 Genzyme Corporation Glucosylceramide synthase inhibitors
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Also Published As

Publication number Publication date
BR112021015172A2 (pt) 2021-09-28
SG11202107842QA (en) 2021-08-30
WO2020163245A1 (en) 2020-08-13
JP2022519274A (ja) 2022-03-22
KR20210123353A (ko) 2021-10-13
AU2020218496A1 (en) 2021-08-26
WO2020163244A1 (en) 2020-08-13
US20220016092A1 (en) 2022-01-20
TW202045167A (zh) 2020-12-16
KR20210123352A (ko) 2021-10-13
EP3920913A1 (en) 2021-12-15
JP2022520747A (ja) 2022-04-01
EP3920914A1 (en) 2021-12-15
CA3128039A1 (en) 2020-08-13
IL285187A (en) 2021-09-30
MX2021009384A (es) 2021-09-10
BR112021015099A2 (pt) 2021-10-05
IL285304A (en) 2021-09-30
CA3128041A1 (en) 2020-08-13
AU2020217659A1 (en) 2021-08-26
TW202045168A (zh) 2020-12-16
US20220023273A1 (en) 2022-01-27
CN113645969A (zh) 2021-11-12
SG11202107844UA (en) 2021-08-30
CN113710249A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
NZ602510A (en) Treatment of lupus nephritis using laquinimod
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
MX2012012952A (es) Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina.
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
IN2014CN03234A (es)
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
NZ602777A (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
MX356873B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BR112013021798A2 (pt) 1,4 tiazepinaas/sulfonas como inibidores de bace1 e/ou bace2
BR112016015763B8 (pt) preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
CR20210630A (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2021009383A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.